The role of FOLFOXIRI and bevacizumab in mCRC: case studies

GI cancer

23 Feb 2022

In this video Professor Chris Karapetis leads a case-study based discussion on two clinical conundrums:

  1. What is the role of FOLFOXIRI in mCRC?
  2. Where does bevacizumab fit in for potentially operable mCRC?

Professor Chris Karapetis is Head of Medical Oncology, Flinders Medical Centre; Network Director of Cancer Services, Southern Area LHN, Adelaide. He is also Director of Clinical Research in Medical Oncology, Flinders Medical Centre and Flinders Centre for Innovation in Cancer, Adelaide.

(21 minutes)

This video is part of a series in which leading experts describe their approaches to common clinical challenges in mCRC through case-based discussion.

Other videos in the series include:

These videos were created independently by the limbic. All case studies were developed by the presenters and views are those of the presenters alone.

Thank you to MSD Australia for providing a non-restrictive educational grant that made this project possible.

Already a member?

Login to keep reading.

OR
Email me a login link